{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Hepatitis+C+Virus&page=3",
    "query": {
      "condition": "Chronic Hepatitis C Virus",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 490,
    "total_pages": 49,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Hepatitis+C+Virus&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Hepatitis+C+Virus&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-03T02:59:17.347Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00248339",
      "title": "Trial of Peg-interferon Plus Epoetin-alfa for Treatment of Chronic Hepatitis C Virus Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Peginterferon-alpha-2b (PEG-Intron)",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Epoetin-alpha (Procrit)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2002-05",
      "completion_date": "2005-07",
      "has_results": false,
      "last_update_posted_date": "2017-03-20",
      "last_synced_at": "2026-10-03T02:59:17.347Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00248339"
    },
    {
      "nct_id": "NCT01290965",
      "title": "Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "SCY-635",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Scynexis, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 57,
      "start_date": "2007-04",
      "completion_date": "2009-01",
      "has_results": false,
      "last_update_posted_date": "2014-11-06",
      "last_synced_at": "2026-10-03T02:59:17.347Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Richmond, Virginia",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01290965"
    },
    {
      "nct_id": "NCT01431898",
      "title": "Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "GS-9669 tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Match GS-9669 tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 82,
      "start_date": "2011-09",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2012-07-25",
      "last_synced_at": "2026-10-03T02:59:17.347Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • DeLand, Florida • Orlando, Florida + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Willingboro",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01431898"
    },
    {
      "nct_id": "NCT02114151",
      "title": "Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C Virus Infection"
      ],
      "interventions": [
        {
          "name": "Simeprevir",
          "type": "DRUG"
        },
        {
          "name": "Sofosbuvir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Infectious Diseases BVBA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 103,
      "start_date": "2014-04",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2016-04-04",
      "last_synced_at": "2026-10-03T02:59:17.347Z",
      "location_count": 32,
      "location_summary": "Dothan, Alabama • Bakersfield, California • Chula Vista, California + 29 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02114151"
    },
    {
      "nct_id": "NCT06868264",
      "title": "C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HEPATITIS C VIRUS CHRONIC INFECTION"
      ],
      "interventions": [
        {
          "name": "Bemnifosbuvir-Ruzasvir (BEM/RZR)",
          "type": "DRUG"
        },
        {
          "name": "Sofosbuvir-Velpatasvir (SOF/VEL)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Atea Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 880,
      "start_date": "2025-04-07",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-05",
      "last_synced_at": "2026-10-03T02:59:17.347Z",
      "location_count": 96,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 84 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06868264"
    },
    {
      "nct_id": "NCT03092375",
      "title": "Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C",
        "HCV"
      ],
      "interventions": [
        {
          "name": "Glecaprevir/Pibrentasvir (G/P) 300mg/120mg",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin 200Mg Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 177,
      "start_date": "2017-04-20",
      "completion_date": "2020-02-06",
      "has_results": true,
      "last_update_posted_date": "2020-02-26",
      "last_synced_at": "2026-10-03T02:59:17.347Z",
      "location_count": 31,
      "location_summary": "Palo Alto, California • San Francisco, California • Washington D.C., District of Columbia + 22 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03092375"
    },
    {
      "nct_id": "NCT01500772",
      "title": "Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Alisporivir",
          "type": "DRUG"
        },
        {
          "name": "Peginterferon alfa-2a",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Debiopharm International SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 6,
      "start_date": "2012-03",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2016-08-01",
      "last_synced_at": "2026-10-03T02:59:17.347Z",
      "location_count": 26,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01500772"
    },
    {
      "nct_id": "NCT00743795",
      "title": "Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HCV Infection"
      ],
      "interventions": [
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "GS-9190",
          "type": "DRUG"
        },
        {
          "name": "Peginterferon Alfa 2a",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 252,
      "start_date": "2008-10",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2013-11-05",
      "last_synced_at": "2026-10-03T02:59:17.347Z",
      "location_count": 48,
      "location_summary": "Anaheim, California • Los Angeles, California • Newport Beach, California + 37 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Clemente",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00743795"
    },
    {
      "nct_id": "NCT02349048",
      "title": "Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C Virus"
      ],
      "interventions": [
        {
          "name": "Simeprevir 150 mg",
          "type": "DRUG"
        },
        {
          "name": "Daclatasvir 60 mg",
          "type": "DRUG"
        },
        {
          "name": "Sofosbuvir 400 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 68,
      "start_date": "2015-01",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2017-03-01",
      "last_synced_at": "2026-10-03T02:59:17.347Z",
      "location_count": 7,
      "location_summary": "Bakersfield, California • Jacksonville, Florida • Lutherville, Maryland + 4 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Lutherville",
          "state": "Maryland"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02349048"
    },
    {
      "nct_id": "NCT01446250",
      "title": "Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Alisporivir",
          "type": "DRUG"
        },
        {
          "name": "Boceprevir",
          "type": "DRUG"
        },
        {
          "name": "Peginterferon alfa-2a",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Debiopharm International SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 8,
      "start_date": "2011-12",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2017-01-16",
      "last_synced_at": "2026-10-03T02:59:17.347Z",
      "location_count": 2,
      "location_summary": "Beverly Hills, California • Baltimore, Maryland",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01446250"
    }
  ]
}